This review highlights the need to recognize and manage the risk of cardiovascular complications associated with taxane use in both oncology and interventional cardiology.
Heightened vigilance for taxane cardiotoxicity is warranted across oncology and interventional cardiology; leaves open the need for prospective trials to guide management.
Taxanes are cytotoxic drugs that stabilize cellular microtubules and are among the most active of the antineoplastic agents being widely used in the treatment of cancer patients. Furthermore, taxanes comprise a valuable tool in interventional cardiology. Following treatment with taxanes, in many patients, the risk of cardiovascular complications has recently been noted. This review examines the cardiac toxicity of treatment with taxanes and their use in cardiology and analyzes issues in clinical practice.
No takes yet. Share an insight, caveat, or question.
Peroukides et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: